Expertise in
28
conditions

Mariya Moosajee

London, ENG, GB 
Expertise in
28
conditions
London, ENG, GB 

Overview

Mariya Moosajee practices practicing medicine in London, United Kingdom.

Ms. Moosajee is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Charles Bonnet Syndrome, Choroideremia, Microphthalmia, Vitrectomy, and Cataract Removal.

She is actively involved in clinical research, co-authoring 174 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

London, ENG EC1V2PD, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug, Other
Study Drug: QR-421a
Study Phase: Phase 2/Phase 3
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Enrollment Status: Terminated
Publish Date: July 12, 2024
Intervention Type: Drug, Other
Study Drug: Ultevursen
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

174 Total Publications

Association of ABHD12 Variants with the Spectrum of PHARC Syndrome Phenotypes.
Association of ABHD12 Variants with the Spectrum of PHARC Syndrome Phenotypes.
Journal: International journal of molecular sciences
Published: June 29, 2026

Frequently Asked Questions about Mariya Moosajee

Is Mariya Moosajee a top-rated expert for Charles Bonnet Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Mariya Moosajee is classified as an Elite expert for Charles Bonnet Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mariya Moosajee participate in research or clinical trials?

Yes. Mariya Moosajee has published 174 articles and abstracts on conditions like Charles Bonnet Syndrome. You can view a list of Mariya Moosajee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Moosajee's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 14 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile